Ziyuglycoside I solid dispersion body and preparation method thereof

A technology of solid dispersion and eucalyptus saponins, applied in the field of medicine, can solve problems such as difficult to obtain, poor efficacy of eucalyptus saponins I, and elevated blood cell levels

Inactive Publication Date: 2017-04-26
SICHUAN YINGLU WEITE PHARMA TECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in actual use, it has been found that Sanguisaponin Ⅰ is not effective, and it is often difficult to achieve a good effect of increasing blood cell levels and treating bone marrow suppression when used alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ziyuglycoside I solid dispersion body and preparation method thereof
  • Ziyuglycoside I solid dispersion body and preparation method thereof
  • Ziyuglycoside I solid dispersion body and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 The preparation of Sangui saponin I solid dispersion of the present invention

[0024] Prescription: Burnet Saponin Ⅰ 1g, PVP K30 8g

[0025] Preparation method: Take the prescribed amount of burnet saponin Ⅰ, add 100ml of absolute ethanol and ultrasonically dissolve it, and obtain solution 1. Separately take the prescribed amount of PVP K30, add 4ml of absolute ethanol and sonicate until dissolved to obtain solution 2. Stir solution 2 on a constant temperature magnetic stirrer, and slowly add solution 1 to solution 2 with a dropper. After all solution 1 is added to solution 2, let the mixture stir for four hours on a constant temperature magnetic stirrer. Pour the mixed solution into an evaporating dish, put it on a 60°C water bath, evaporate to dryness, and grind the evaporated matter to obtain a solid dispersion.

Embodiment 2

[0026] Embodiment 2 Preparation of Burnet Saponin I Solid Dispersion of the Present Invention

[0027] Prescription: Burnet Saponin Ⅰ 5g, PVP K30 20g

[0028] Preparation method: Take the prescribed amount of burnet saponin Ⅰ, add 500ml of absolute ethanol and ultrasonically dissolve it, and obtain solution 1. Separately take the prescribed amount of PVP K30, add 20ml of absolute ethanol and sonicate until dissolved to obtain solution 2. Stir solution 2 on a constant temperature magnetic stirrer, and slowly add solution 1 to solution 2 with a dropper. After all solution 1 is added to solution 2, let the mixture stir for four hours on a constant temperature magnetic stirrer. Pour the mixed solution into an evaporating dish, put it on a 60°C water bath, evaporate to dryness, and grind the evaporated matter to obtain a solid dispersion.

Embodiment 3

[0029] Embodiment 3 Preparation of Burnet Saponin I Solid Dispersion of the Present Invention

[0030] Prescription: Burnet Saponin Ⅰ 10g, PVP K30 100g

[0031] Preparation method: Take the prescribed amount of Saponin I from Sangui, add 1000ml of absolute ethanol and ultrasonically dissolve it, and obtain solution 1. Take another prescribed amount of PVP K30, add 40ml of absolute ethanol and sonicate until dissolved to obtain solution 2. Stir solution 2 on a constant temperature magnetic stirrer, and slowly add solution 1 to solution 2 with a dropper. After all solution 1 is added to solution 2, let the mixture stir for four hours on a constant temperature magnetic stirrer. Pour the mixed solution into an evaporating dish, put it on a 60°C water bath, evaporate to dryness, and grind the evaporated matter to obtain a solid dispersion.

[0032] The beneficial effects of the present invention are demonstrated through experimental examples below.

[0033] Dissolution test meth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a ziyuglycoside I solid dispersion body, which is prepared from the following raw material and auxiliary material by weight: 1 part of ziyuglycoside I, and 4-30 parts of povidone. According to the present invention, the quality evaluation experiment results show that the povidone is used as the carrier material so as to significantly improve the solubility of the ziyuglycoside I, and the dissolution rate of the solid dispersion body is up to 88%; the efficacy experiment results show that the ziyuglycoside I solid dispersion body can significantly improve the numbers of WBC, RBC, PLT, NEUT and HGB in peripheral blood compared to the model group, and provides the potency significantly superior to the ziyuglycoside I raw drug; and with the application of the ziyuglycoside I to prepare into the solid dispersion body, the bioavailability of the main drug can be improved, and the effects of blood cell number increasing and myelosuppression prevention and treatment are enhanced.

Description

technical field [0001] The invention relates to a solid dispersion of burnet saponin I and a preparation method thereof, belonging to the field of medicine. Background technique [0002] Myelosuppression is a clinically common hematopoietic system disease, which can occur in radiotherapy and / or chemotherapy of tumor diseases in various systems, radiation injury caused by ionizing radiation, viral hepatitis, parvovirus infection or drugs (chloramphenicol) , benzene, sulfonamides, antiepileptics, sedatives, antithyroid drugs, antidiabetics, antimalarials, sleeping pills) and other factors. Myelosuppression can cause damage to the bone marrow microenvironment, hematopoietic stem cells, hematopoietic growth factors, etc., and the first, second or third lineage of myeloid, erythrocytic, and megakaryocyte systems are inhibited. Agranulocytosis can cause serious infection; red blood cell decrease can cause severe anemia; platelet decrease can cause severe bleeding and even death. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/14A61K31/704A61K47/32A61P7/06A61P7/00
CPCA61K9/146A61K31/704
Inventor 杨世林
Owner SICHUAN YINGLU WEITE PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap